Current research

The EHE Rare Cancer Charity (UK) will continue to publish details of the research scientists it supports with grants to fund research into EHE. Currently, we are focused on funding the international EHE research programme led by Dr Brian Rubin, as well as individual projects that are identified and confirmed by the Charity’s Research and Medical Advisory Team to be of value in progressing our understanding of EHE. Details and links to relevant information about these researchers are provided below.


Dr Brian Rubin

Dr Rubin initiated and leads the only coordinated and collaborative research programme into EHE of which the EHE sister foundations/charities are aware. Dr Rubin is certified in anatomic pathology by the American Board of Pathology. He specializes in the diagnosis of diseases of bone and soft tissue and is an expert in the diagnosis of sarcomas. His areas of special interest include bone and soft tissue pathology, cancer genetics and targeted cancer therapies.

Dr Rubin is a member of the Anatomic Pathology Department of the Cleveland Clinic. He currently holds the following positions; Professor and Chair of Pathology; Director, Soft Tissue Pathology; Director, Bone and Soft Tissue Pathology Fellowship Program, at the Robert J. Tomsich Pathology & Laboratory Medicine Institute and Department of Cancer Biology Cleveland Clinic and Lerner Research Institute. He is a member of: the International Society of Bone and Soft Tissue Pathology; the College of American Pathologists; the Connective Tissue Oncology Society; the United States and Canadian Academy of Pathology and the American Association for the Advancement of Science.

If your medical team wish to contact Dr Rubin, he can be contacted through his email address at

For information about Dr Rubin’s EHE research, please go to the PROGRAMME DETAILS page within this section of the website.


Dr John Lamar

Dr. Lamar grew up in the USA just outside of Buffalo, NY.  He obtained his bachelor’s degree in biochemistry from the State University of New York at Geneseo. He then worked as a research technician for two years before joining the Ph.D. program at Albany Medical College, in Albany NY. His Ph.D. work focused on a cell surface adhesion receptor and its roles in cancer growth and tumor cell invasion. In 2008, he began his postdoctoral fellowship at Massachusetts Institute of Technology (MIT), where he studied mechanisms of cancer metastasis. It was here that he began his work on the Hippo-YAP/TAZ pathway. In 2015, he started his own laboratory as Assistant Professor at Albany Medical College in the Department of Molecular and Cellular Physiology. His laboratory is investigating the potential to target the Hippo-YAP/TAZ pathway as a treatment for metastatic cancers. His work with this pathway is also how he became interested in EHE and he is using his lab’s tools and model systems to try to identify ways that the TAZ-CAMTA1 fusion protein that drives EHE can be inhibited.  Dr. Lamar and Guy Weinberg also co-organize an annual workshop that aims to connect researchers in the Hippo-YAP/TAZ field with those studying EHE.


Dr Valerie Kouskoff

Dr Valerie Kouskoff heads a research group at the University of Manchester, UK in the Division of Developmental Biology and Medicine. She has extensive experience in the fields of haematopoiesis and immunology. During her PhD in Strasbourg, France and post-doctoral training in Denver, USA, she focused her studies on the developmental specification of T and B lymphocytes and how the uncontrolled activation of these cells leads to auto-immune diseases. After this training in basic and applied immunology, she joined the laboratory of Professor Keller at Mount Sinai Hospital in New York, USA to study the sequential cellular and molecular steps leading to the specification of mesoderm to cardiovascular lineages upon the in vitro differentiation of embryonic stem cells.

At the end of 2003, she established her own programme of research at the Cancer Research UK Manchester Institute, then in 2016 moved her laboratory to the Division of Development Biology and Medicine. Since establishing her laboratory, her group has focused on further understanding the molecular and cellular mechanisms underlying the formation of the cardiovascular system. Over the years, her group has made seminal contributions in defining how this system is established during embryonic life. Using in vitro and in vivo models, one major aim of her team focused on the identification of novel regulators of haematopoietic and endothelial specification and how those are disrupted in malignancies and diseases.

For information about Dr Kouskoff’s EHE research project investigating how EHE affects endothelial cells, please go to the UK EHE RESEARCH page within this section of the website.


Dr Fredericus Van Eeden

Dr Van Eeden has been involved in zebrafish research for more than 25 years and has been contributing to the development of this unique model-system in numerous ways.  During his PhD with Nobel-Laureate Prof. Nüsslein-Volhard, in the Max Planck institute in Tübingen, he participated in a pioneering mutagenesis screen that catalysed the use of zebrafish as a genetically amenable vertebrate model organism (published in a dedicated issue of Development in 1996). After a post-doc in the St Johnston laboratory in Cambridge working with Drosophila, he returned to the zebrafish in the Hubrecht Lab in Utrecht. Here he collaborated with several groups and the Sanger centre, to develop reverse genetics techniques as a way to create human genetic disease models in this organism. This led to the establishment of TILLING as a high throughput way to create knockouts. He was attracted to Sheffield because of its excellent fish facilities and expertise. In Sheffield he continued to work on knockout technologies, adopting first Zinc fingers, TALENs, and finally CRISPR to generate mutants of choice. In Sheffield they are exploiting their understanding of fish embryo development to dissect disease processes phenotypically and molecularly. They are also using their larval disease models to perform in vivo chemical screens and identify drug-leads that might one day help human patients.

For information about Dr Van Eeden’s EHE research project involving the development of a zebrafish model of EHE, please go to the UK EHE RESEARCH page within this section of the website.


Dr Paul Huang

Dr Paul Huang leads the Molecular and Systems Oncology Team in the Division of Molecular Pathology at the Institute of Cancer Research, London.

Originally from Singapore, he received his BSc in Biotechnology from Imperial College London in 2004. He trained in Dr Forest White’s laboratory at Massachusetts Institute of Technology (MIT) where he received a PhD in Biological Engineering in 2008

Dr Huang joined the ICR in 2009 as an Institute Fellow and was awarded a Sir Henry Wellcome Fellowship by the Wellcome Trust (2009-12). He was promoted to a tenure-track Career Development Faculty (2012-17) in the Division of Cancer Biology. He is currently a tenured Career Faculty (2017-present) within the Division of Molecular Pathology and holds a Cancer Research UK Career Establishment Award.

His research focuses on the use of systems biology and molecular pathology to understand drug resistance in sarcomas and lung cancer with the goal of developing biomarkers and new therapies for these diseases.

Dr Huang serves as a member of several panels including the NCRI Sarcoma Clinical Studies Group, Research Advisory Committee of Sarcoma UK and the Scientific Evaluation Committee of the European Research Area Network (ERA-NET) TRANSCAN-2 for joint translational cancer research.

Dr Huang gained the title of Reader at the ICR in 2019.

For information about the Joint Royal Marsden-ICR Sarcoma Research Unit’s project to develop a UK National EHE Biobank, please go to the UK EHE RESEARCH page within this section of the website.